drugset
drugset / Trial / NCT05397041

A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers

NCT05397041 ↗

Phase 1 Completed 81 enrolled Bright Minds Biosciences Pty Ltd
RandomizedSequentialQuadruple-blindTreatment

Summary

This study is designed as a single centre, double blind, placebo controlled, randomized, SAD/FE/MAD, safety, tolerance and PK study of BMB-101 in healthy adult subjects. The study will be conducted as a 3-part study.

Timeline

Start
2022-06-06
Primary completion
2023-05-04
Completion
2023-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BMB-101 Unknown — Oral

Indications

No indication recorded.